Group I Paks as therapeutic targets in NF2-deficient meningioma

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder causing central nervous system tumors, primarily schwannomas and meningiomas.
• NF2 gene mutations are implicated in sporadic meningiomas, but malignant transformation mechanisms are not fully understood.
• The NF2 protein, Merlin, regulates Group I p21-activated kinases (Paks); their dysregulation may drive meningioma progression.

Purpose of the Study:

• To investigate the anti-tumor effects of Group I Pak inhibitors in NF2-deficient meningiomas.
• To assess the impact of Pak inhibitors on meningioma cell proliferation, motility, and signaling pathways.
• To evaluate the efficacy of Pak inhibitors in preclinical models of NF2-deficient meningiomas.

Main Methods:

• Treatment of benign (Ben-Men1) and malignant (KT21-MG1) NF2-/- meningioma cells with Pak inhibitors (Frax597, 716, 1036) in vitro.
• Analysis of cell proliferation, motility, and key signaling molecules (Mek, S6, cyclin D1).
• In vivo efficacy study using intracranial xenografts of luciferase-expressing KT21-MG1 and Ben-Men1 cells in an orthotopic mouse model.

Main Results:

• Pak inhibitors significantly suppressed proliferation and motility of both benign and malignant meningioma cells.
• Inhibition of Mek and S6 phosphorylation and decreased cyclin D1 expression were observed.
• Significant tumor suppression was achieved in vivo with all three Pak inhibitors, accompanied by increased apoptosis.

Conclusions:

• Group I Pak inhibitors demonstrate potent anti-tumor activity against NF2-deficient meningiomas in vitro and in vivo.
• These findings highlight the therapeutic potential of Pak inhibitors for treating NF2-related meningiomas.
• Targeting Pak signaling represents a promising strategy for managing NF2-associated central nervous system tumors.